GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (NAS:BOLT) » Definitions » Net Income (Continuing Operations)

BioLight Life Sciences (BioLight Life Sciences) Net Income (Continuing Operations) : $-7.18 Mil (TTM As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is BioLight Life Sciences Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. BioLight Life Sciences's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was $-1.99 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.18 Mil.


BioLight Life Sciences Net Income (Continuing Operations) Historical Data

The historical data trend for BioLight Life Sciences's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLight Life Sciences Net Income (Continuing Operations) Chart

BioLight Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.56 -3.70 -0.09 -2.27 -7.18

BioLight Life Sciences Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.08 0.51 -2.78 -5.19 -1.99

BioLight Life Sciences Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-7.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLight Life Sciences  (NAS:BOLT) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


BioLight Life Sciences Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLight Life Sciences (BioLight Life Sciences) Business Description

Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101
BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.

BioLight Life Sciences (BioLight Life Sciences) Headlines

From GuruFocus

Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

By Value_Insider Value_Insider 12-14-2022

Bolt Biotherapeutics to Present at February Investor Conferences

By Stock market mentor Stock market mentor 02-01-2023